HUE026901T2 - 15-HEPE-containing compositions, and a method for their use - Google Patents

15-HEPE-containing compositions, and a method for their use Download PDF

Info

Publication number
HUE026901T2
HUE026901T2 HUE13176516A HUE13176516A HUE026901T2 HU E026901 T2 HUE026901 T2 HU E026901T2 HU E13176516 A HUE13176516 A HU E13176516A HU E13176516 A HUE13176516 A HU E13176516A HU E026901 T2 HUE026901 T2 HU E026901T2
Authority
HU
Hungary
Prior art keywords
hepe
use according
disease
abouto
composition
Prior art date
Application number
HUE13176516A
Other languages
English (en)
Hungarian (hu)
Inventor
Jonathan Rowe
Kevin Duffy
John Climax
Original Assignee
Dignity Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dignity Sciences Ltd filed Critical Dignity Sciences Ltd
Publication of HUE026901T2 publication Critical patent/HUE026901T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
HUE13176516A 2013-01-30 2013-07-15 15-HEPE-containing compositions, and a method for their use HUE026901T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1301626.6A GB201301626D0 (en) 2013-01-30 2013-01-30 Composition comprising 15-OHEPA and methods of using the same

Publications (1)

Publication Number Publication Date
HUE026901T2 true HUE026901T2 (en) 2016-07-28

Family

ID=47891001

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13176516A HUE026901T2 (en) 2013-01-30 2013-07-15 15-HEPE-containing compositions, and a method for their use

Country Status (27)

Country Link
US (6) US20150224076A1 (enExample)
EP (2) EP3058943B1 (enExample)
JP (2) JP6363104B2 (enExample)
KR (6) KR20240011872A (enExample)
CN (2) CN105120872B (enExample)
AU (2) AU2014211628B2 (enExample)
BR (1) BR112015018270A2 (enExample)
CA (1) CA2897343C (enExample)
CY (1) CY1117209T1 (enExample)
DK (1) DK2762143T3 (enExample)
ES (2) ES2759448T3 (enExample)
GB (1) GB201301626D0 (enExample)
HR (1) HRP20160203T1 (enExample)
HU (1) HUE026901T2 (enExample)
IL (3) IL239893A (enExample)
MX (2) MX364646B (enExample)
NZ (1) NZ709803A (enExample)
PH (1) PH12015501582B1 (enExample)
PL (1) PL2762143T3 (enExample)
PT (1) PT2762143E (enExample)
RS (1) RS54584B1 (enExample)
RU (2) RU2671208C2 (enExample)
SG (2) SG11201505457PA (enExample)
SI (1) SI2762143T1 (enExample)
SM (1) SMT201600069B (enExample)
WO (1) WO2014118097A1 (enExample)
ZA (2) ZA201505018B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
US10017453B2 (en) 2013-11-15 2018-07-10 Ds Biopharma Limited Pharmaceutically acceptable salts of fatty acids
AU2015204531B2 (en) * 2014-01-10 2019-11-14 Afimmune Limited Pharmaceutical compositions comprising 15-HEPE and methods of treating asthma and lung disorders using same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
CN113893240A (zh) * 2015-01-16 2022-01-07 艾菲穆恩有限公司 包含15-hepe的组合物和其使用方法
KR20240033300A (ko) 2015-04-28 2024-03-12 바스프 에이에스 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도
MA47141A (fr) * 2015-05-13 2019-11-06 Ds Biopharma Ltd Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
US20170020836A1 (en) * 2015-07-21 2017-01-26 Dignity Sciences Limited Compositions Comprising 15-HEPE and Methods of Treating or Preventing Cancer and Neurologic Disease
RU2737089C2 (ru) 2015-12-18 2020-11-24 Эфиммьюн Лимитед Композиции, содержащие 15-hepe, и способы их применения
EP3720431B1 (en) 2017-12-06 2024-10-30 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN115215725A (zh) * 2021-04-15 2022-10-21 宋晓瑜 一种制备乙酸薰衣草酯及薰衣草醇的方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
AU702240B2 (en) 1993-10-01 1999-02-18 R.P. Scherer Corporation Methods and compositions for dispensing fragrances
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
EP1762557B1 (en) * 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
CN1268328C (zh) 2001-05-30 2006-08-09 拉克斯戴尔有限公司 辅酶q与二十碳五烯酸(epa)
CN1250230C (zh) * 2001-09-30 2006-04-12 中国药品生物制品检定所 海狗油作为制备治脂肪肝药的应用
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
US20070105954A1 (en) 2003-12-31 2007-05-10 Ingennus Limited Formulation containing a carboxylic acid or an ester thereof
WO2005102309A2 (en) 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
CN101043884A (zh) 2004-07-01 2007-09-26 谢彭斯眼科研究公司 用于治疗眼部疾病和病症的组合物和方法
US20070265340A1 (en) * 2006-01-05 2007-11-15 Shalwitz Robert A Treatment of fatty liver
EP3285072B1 (en) 2006-08-08 2020-04-15 Metabolon, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
EP2143430B1 (en) * 2007-03-30 2015-09-23 Kowa Company, Ltd. Drug for preventing and/or treating fatty liver or nonalcoholic fatty liver disease
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
US20110105510A1 (en) * 2008-06-17 2011-05-05 Hiroshi Ishikawa Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
US8853437B2 (en) * 2009-02-20 2014-10-07 The University Of Tokyo Anti-inflammatory compounds
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
JP5909183B2 (ja) * 2010-08-19 2016-04-26 国立大学法人 東京大学 オメガ３系脂肪酸由来の新規抗炎症性代謝物
WO2012031125A2 (en) 2010-09-01 2012-03-08 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
EP2768496A1 (en) 2011-10-19 2014-08-27 Dignity Sciences Limited Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
AU2012345942A1 (en) 2011-11-29 2014-06-12 Dignity Sciences Limited Compositions comprising 20-carbon fatty acids and methods of making and using same
LT2800563T (lt) 2012-01-06 2018-10-25 Omthera Pharmaceuticals Inc. Laisvos rūgšties formos omega-3 polinesočiųjų riebalų rūgščių dpa praturtintos kompozicijos
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
ES2946109T3 (es) 2012-05-10 2023-07-12 Solutex Na Llc Aceites con actividad antiinflamatoria que contienen mediadores pro-resolutivos especializados naturales y sus precursores
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
US20170020836A1 (en) * 2015-07-21 2017-01-26 Dignity Sciences Limited Compositions Comprising 15-HEPE and Methods of Treating or Preventing Cancer and Neurologic Disease
RU2737089C2 (ru) 2015-12-18 2020-11-24 Эфиммьюн Лимитед Композиции, содержащие 15-hepe, и способы их применения

Also Published As

Publication number Publication date
MX2015009803A (es) 2015-10-29
EP3058943B1 (en) 2019-09-25
MX2019005082A (es) 2019-08-12
IL265876A (en) 2019-06-30
ES2759448T3 (es) 2020-05-11
WO2014118097A1 (en) 2014-08-07
KR20230047201A (ko) 2023-04-06
MX364646B (es) 2019-05-03
EP2762143B1 (en) 2015-12-02
EP2762143A1 (en) 2014-08-06
IL239893A (en) 2017-04-30
IL251639A0 (en) 2017-06-29
PH12015501582A1 (en) 2015-10-05
JP2018172409A (ja) 2018-11-08
US20150224076A1 (en) 2015-08-13
KR20150112995A (ko) 2015-10-07
AU2014211628B2 (en) 2018-04-19
RU2015136849A (ru) 2017-03-06
RS54584B1 (sr) 2016-08-31
JP6363104B2 (ja) 2018-07-25
ZA201505018B (en) 2017-01-25
AU2018206685A1 (en) 2018-08-02
PL2762143T3 (pl) 2016-06-30
SG11201505457PA (en) 2015-08-28
KR102274963B1 (ko) 2021-07-08
KR102514913B1 (ko) 2023-03-27
US20200069626A1 (en) 2020-03-05
PH12015501582B1 (en) 2019-10-25
RU2018136872A (ru) 2018-11-27
ZA201605125B (en) 2018-06-27
DK2762143T3 (en) 2016-03-07
HRP20160203T1 (hr) 2016-03-25
US20210244697A1 (en) 2021-08-12
AU2014211628A1 (en) 2015-07-30
KR20250105691A (ko) 2025-07-08
CY1117209T1 (el) 2017-04-05
KR102434817B1 (ko) 2022-08-19
HK1200351A1 (en) 2015-08-07
KR20210088733A (ko) 2021-07-14
SI2762143T1 (sl) 2016-04-29
US10813903B2 (en) 2020-10-27
CN111214464A (zh) 2020-06-02
RU2671208C2 (ru) 2018-10-30
GB201301626D0 (en) 2013-03-13
US20250186384A1 (en) 2025-06-12
KR20220119524A (ko) 2022-08-29
CA2897343A1 (en) 2014-08-07
CN105120872A (zh) 2015-12-02
US20220347147A1 (en) 2022-11-03
EP3058943A1 (en) 2016-08-24
BR112015018270A2 (pt) 2017-07-18
CN105120872B (zh) 2020-01-10
IL239893A0 (en) 2015-08-31
ES2564025T3 (es) 2016-03-17
PT2762143E (pt) 2016-03-28
CA2897343C (en) 2021-03-16
SMT201600069B (it) 2016-04-29
JP2016511753A (ja) 2016-04-21
KR20240011872A (ko) 2024-01-26
US20210228524A1 (en) 2021-07-29
NZ709803A (en) 2020-05-29
SG10201806854XA (en) 2018-09-27

Similar Documents

Publication Publication Date Title
US20250186384A1 (en) Compositions comprising 15-ohepa and methods of using the same
AU2022291628B2 (en) Compositions comprising 15-HEPE and methods of using the same
WO2016113635A1 (en) Compositions comprising 15-hepe and methods of using the same
HK1200351B (en) Compositions comprising 15-hepe and methods of using the same